CD4 and neoplasm: In preclinical models, niraparib has been shown to promote tumour immune cell infiltration by CD4+ and CD8+ T cells, induce activation of interferon signaling and work synergistically to decrease tumour volume when combined with the PD-L1 checkpoint inhibitor pembrolizumab [191].